Product Details
| Product Name:
Sertindole |
CAS No.:
106516-24-9 |
| Purity:
99.74% |
Supply Ability:
10g |
| Release date:
2025/07/15 |
Product Introduction
Bioactivity
| Name | Sertindole |
| Description | Sertindole (Lu 23-174) is an atypical antipsychotic that binds to dopamine D2 receptors and serotonin (5-HT) receptor subtypes 5-HT1D, 5-HT2A, and 5-HT2C, with Kds of 2.7, 20, 0.14, and 6 nM, respectively. |
| Animal Research | Rats were treated acutely with vehicle or drugs, and extracellular levels of neurotransmitters were assessed by microdialysis in freely moving animals[1]. |
| In vivo | In vivo, sertindole (10 mg/kg) increases extracellular dopamine, acetylcholine (ACh), and glutamate levels in the medial prefrontal cortex in conscious rats[1].Sertindole (2.5 mg/kg) reverses ketamine-induced impairments in the extradimensional shift stage of the attentional set-shifting task (ASST) in rats[2].It reverses phencyclidine (PCP)-induced selective reversal learning deficits in rats and subchronic PCP-induced deficits in the novel object recognition task in mice[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (113.39 mM), Sonication is recommended.
|
| Keywords | U87-MG | U251 | U118-MG | T47D | SW620 | SW480 | SUM159 | SGC-7901 | Sertindole | Serotonin Receptor | NCI-H661 | NCI-H460 | NCI-H446 | MKN45 | MCF-7 | MCF-10A | K562 | Jurkat | Inhibitor | inhibit | HT-29 | HepG2 | HCT-15 | DopamineReceptor | Dopamine Receptor | Dopamine | D2 | COLO205 | CCRF-CEM | BGC-823 | Beta Receptor | Bel-7402 | Autophagy | antipsychotic activity | anti-proliferative activity | AGS | AdrenergicReceptor | Adrenergic Receptor | A549 | A172 | 801-D | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT Receptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Valproic Acid | Curcumin | Paeonol | Naringin | Alginic acid | Gefitinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:2295-58-1
$30.00 / 50mg
-
CAS:1025720-94-8
$30.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.10/1g |
VIP5Y
|
Dideu Industries Group Limited
|
2021-07-23 |
United States